Crestline Management LP Boosts Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Crestline Management LP lifted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 78.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 452,455 shares of the biopharmaceutical company's stock after purchasing an additional 198,685 shares during the period. Crestline Management LP owned 0.34% of Dynavax Technologies worth $5,778,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. increased its stake in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 1,169 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 2,034 shares during the period. GAMMA Investing LLC raised its position in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies during the 4th quarter valued at approximately $71,000. Finally, Nisa Investment Advisors LLC raised its stake in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. The Goldman Sachs Group cut their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. StockNews.com cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities dropped their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Price Performance

NASDAQ DVAX traded up $0.33 on Monday, hitting $9.74. The stock had a trading volume of 863,011 shares, compared to its average volume of 2,211,435. Dynavax Technologies Co. has a 52-week low of $9.28 and a 52-week high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 54.08 and a beta of 1.26. The firm has a 50-day moving average of $12.24 and a 200-day moving average of $12.58.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Equities analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.